Streck claims that the blood collection tubes in the Roche Ariosa Harmony kit that Cenata uses infringe its patent.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
Among Flatiron's assets is a database developed in collaboration with Foundation Medicine intended to help biopharma firms develop more effective cancer therapies.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
The test reduces hands-on time by enabling labs to simultaneously assess Factor II and Factor V gene mutations from a single patient sample, Roche said.
Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
Pharmaceutical giant Roche has entered into a collaboration with Syapse to widen access to precision oncology technology and services.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.